415908-96-2

Upstream product

• 415908-91-7 2-{4-[(3-amino-2,6-dimethyl-4-pyridinyl)amino]phenyl}ethanol 
• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 15513-48-1 4-chloro-2,6-dimethyl-3-nitropyridine 
• 94838-59-2 tert-butyl 4-aminophenethylcarbamate 
• 13472-00-9 p-Aminophenethylamine 
• 415908-93-9 2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethanol 

Downstream Products

• 415903-37-6 CJ-023423 

Relevant academic research and scientific papers

PROCESS FOR PREPARATION OF GRAPIPRANT

The invention relates to process for the preparation of grapiprant and its intermediates thereof. The invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC. The invention also relates to an amorphous form of grapiprant and process for preparation thereof.

EP4 INHIBITORS AND SYNTHESIS THEREOF

The present invention provides N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide compositions, and the use thereof for treating a proliferative disorder.

CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE

The invention relates to the essentially pure Λ/-[({2-[4-(2-Ethyl-4,6-dimethyl-1 H- imidazo[4,5-c]pyridin-1 -yl)phenyl]ethyl}amino)carbonyl]-4- methylbenzenesulfonamide Polymorph Forms A and B and to processes for the preparation of, compositions containi

COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS

The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory,

Use of EP4 receptor ligands in the treatment of IL-6 involved diseases

Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS

The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.